Sarah Waliany, Hematology and Oncology Fellow at Dana-Farber Cancer Institute, made the following post on Twitter:
“The incomparable Sumanta K. Pal on cardiovascular AEs associated w/ mRCC treatments
Treatment landscape & key trials for mRCC
Treatment decisions in setting of CV comorbidities & tradeoffs
Future directions (HIF2 inhibitors, cellular therapies, bispecific Ab)”
For details click here.
Source: Sarah Waliany/Twitter